Cipher Pharmaceuticals (TSE:CPH - Get Free Report) NASDAQ: CPHR was upgraded by equities research analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating in a research note issued to investors on Tuesday, BayStreet.CA reports. The firm presently has a C$16.00 target price on the stock, up from their prior target price of C$9.50. Stifel Nicolaus' target price would indicate a potential upside of 14.86% from the company's previous close.
Cipher Pharmaceuticals Trading Up 3.6 %
CPH stock traded up C$0.49 during midday trading on Tuesday, hitting C$13.93. The company had a trading volume of 46,534 shares, compared to its average volume of 36,312. The company has a current ratio of 7.96, a quick ratio of 2.67 and a debt-to-equity ratio of 0.38. Cipher Pharmaceuticals has a 52 week low of C$3.45 and a 52 week high of C$14.55. The stock's 50 day moving average price is C$9.52 and its 200 day moving average price is C$8.59. The stock has a market cap of C$335.85 million, a price-to-earnings ratio of 11.33 and a beta of 1.05.
About Cipher Pharmaceuticals
(
Get Free Report)
Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.
Featured Articles
Before you consider Cipher Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cipher Pharmaceuticals wasn't on the list.
While Cipher Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
